"The latest results stated that "more than 90%" patients benefitted. The more than 90% sounds great but in order for it to be approved by FDA, results need to show = to or greater than 95%. Phase 1 was above this, price hit $1.10 Phase 2 was a bit less and all of a sudden a trend in the results is possibly occuring. "
avx did not announce that more than 90% benenfitted, they announced:
"... the proportion of patients with HIV levels below detectable was over 90%".
There is a very big difference!
If you are going to compare data, compare like with like. There is a trend, but it is going the opposite way to what you are suggesting.
AVX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held